Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
bimatoprost 20 µg generation 2 · 1 trial · 2 indications
IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
| Arm | Type | Description |
|---|---|---|
| bimatoprost 20 µg generation 2, bimatoprost 0.03% | OTHER | Single dose of bimatoprost ophthalmic 20 µg generation 2 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months. |
| bimatoprost 15 µg generation 2, bimatoprost 0.03% | OTHER | Single dose of bimatoprost ophthalmic 15 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months. |
| bimatoprost 10 µg generation 2, bimatoprost 0.03% | OTHER | Single dose of bimatoprost ophthalmic 10 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months. |
| bimatoprost 6 µg generation 2, bimatoprost 0.03% | OTHER | Single dose of bimatoprost ophthalmic 6 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months. |
| bimatoprost 15 µg generation 1, bimatoprost 0.03% | OTHER | Single dose of bimatoprost ophthalmic 15 µg generation 1 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months. |
| bimatoprost 10 µg generation 1, bimatoprost 0.03% | OTHER | Single dose of bimatoprost ophthalmic 10 µg generation 1 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months. |
| Name | Type | Description |
|---|---|---|
| bimatoprost 20 µg generation 2 | DRUG | Single dose of bimatoprost ophthalmic administered in the study eye on Day 1. |
| bimatoprost 15 µg generation 2 | DRUG | Single dose of bimatoprost ophthalmic administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). |
| bimatoprost 10 µg generation 2 | DRUG | Single dose of bimatoprost ophthalmic 10 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). |
| bimatoprost 6 µg generation 2 | DRUG | Single dose of bimatoprost ophthalmic 6 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). |
| bimatoprost 15 µg generation 1 | DRUG | Single dose of bimatoprost ophthalmic 15 µg generation 1 administered in the study eye on Day 1. |
| bimatoprost 10 µg generation 1 | DRUG | Single dose of bimatoprost ophthalmic 10 µg generation 1 administered in the study eye on Day 1. |
| bimatoprost 0.03% | DRUG | One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months. |
Inclusion Criteria: * Diagnosis of open angle glaucoma or ocular hypertension Exclusion Criteria: * Uncontrolled medical conditions * Anticipated wearing of contact lenses during the study
Top 3 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular, high elution |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Bimatoprost ophthalmic solution |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | bimatoprost |
Bimatoprost 20 µg generation 2 is an investigational small molecule ophthalmic formulation being developed by AbbVie Inc. (ABBV) for open-angle glaucoma. It is a next-generation version of bimatoprost formulated at a 20 microgram dose, studied in a Phase 1 trial that also enrolled patients with ocular hypertension.
Bimatoprost 20 µg generation 2 is being studied for the treatment of open-angle glaucoma, a condition in which elevated intraocular pressure can damage the optic nerve. The Phase 1 trial for this formulation also included patients with ocular hypertension, a related condition of raised eye pressure.
Bimatoprost 20 µg generation 2 targets PTGFR, the prostaglandin F receptor, and acts as an agonist at this receptor. PTGFR agonism is the established mechanism for bimatoprost-class agents in lowering intraocular pressure in glaucoma.
Bimatoprost 20 µg generation 2 is being developed by AbbVie Inc., which trades under the ticker ABBV. AbbVie is the sponsor of the clinical program evaluating this ophthalmic formulation in glaucoma and ocular hypertension.
Bimatoprost 20 µg generation 2 is in Phase 1 development. It is an investigational formulation and has not been approved by the FDA. The single Phase 1 trial has been completed, and no active trials are currently listed for this specific formulation.
Bimatoprost 20 µg generation 2 was evaluated in one completed Phase 1 trial, NCT01157364, titled Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension. The randomized, double-blind, controlled trial enrolled 109 patients across the United States, Australia, Belgium, Brazil, Canada, Germany, Israel, the Philippines, Singapore, and Spain.